The molecular basis underlying our findings on DLBCL, as in those in other tumor types, in which CXCR7 is a marker for good prognosis may relate to a protective effect reported for CXCR7 expression, which has been always associated with the inhibition of CXCR4-mediated signaling. The gene discussed is ACKR3; the disease is neoplasm.